Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 18;41(3):111496. doi: 10.1016/j.celrep.2022.111496

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Antibodies to the FL-S of other betacoronaviruses are boosted upon SARS-CoV-2 infection and after vaccination to a lesser extent

(A and B) ELISAs were completed to quantify levels of serum antibodies binding to the FL-S protein of other betacoronaviruses (OC43, HKU1, SARS-CoV) and alphacoronavirus (229E) after SARS-CoV-2 infection (A) and mRNA vaccination (B). Paired t tests or one-way ANOVA of log2 transformed antibody titers; ^∗∗∗∗p < 0.0001, ^∗∗∗p < 0.001, ^∗∗p < 0.01, ^∗p < 0.05. Data are representative of two independent experiments.

(C) We calculated fold change in antibody titers against spike before and after seroconversion and pre-/post-prime and boost doses of a SARS-CoV-2 mRNA vaccine. One-way ANOVA of antibody fold change; ^∗∗∗∗p < 0.0001, ^∗∗∗p < 0.001, ^∗∗p < 0.01.